# A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07621159/  
OnCo record `nct07621159` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HDM2017 and fruquintinib in colorectal cancer, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07621159 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-07-15 and due to reach its primary completion in 2027-11-01. Interventions recorded: HDM2017; Fruquintinib. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D); Type, incidence and severity of Adverse Events. Colorectal eligibility wording from the registry: "Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07621159
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy and Safety of HDM2017 in Combination With Standard of Care in Participants With Advanced Colorectal Cancer
- Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07621159: https://clinicaltrials.gov/study/NCT07621159

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [HDM2017](https://onco.cc/drugs/hdm2017/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07621159.json